These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 11227044

  • 1. Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus.
    Treadway JL, Mendys P, Hoover DJ.
    Expert Opin Investig Drugs; 2001 Mar; 10(3):439-54. PubMed ID: 11227044
    [Abstract] [Full Text] [Related]

  • 2. Glycogen phosphorylase inhibitors.
    Henke BR, Sparks SM.
    Mini Rev Med Chem; 2006 Aug; 6(8):845-57. PubMed ID: 16918491
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo.
    Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL.
    Proc Natl Acad Sci U S A; 1998 Feb 17; 95(4):1776-81. PubMed ID: 9465093
    [Abstract] [Full Text] [Related]

  • 4. The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction.
    Baker DJ, Greenhaff PL, MacInnes A, Timmons JA.
    Diabetes; 2006 Jun 17; 55(6):1855-61. PubMed ID: 16731853
    [Abstract] [Full Text] [Related]

  • 5. Human liver glycogen phosphorylase inhibitors bind at a new allosteric site.
    Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR, Mathiowetz AM, McPherson RK, Olson TV, Treadway JL, Hoover DJ.
    Chem Biol; 2000 Sep 17; 7(9):677-82. PubMed ID: 10980448
    [Abstract] [Full Text] [Related]

  • 6. Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition.
    Goyard D, Kónya B, Chajistamatiou AS, Chrysina ED, Leroy J, Balzarin S, Tournier M, Tousch D, Petit P, Duret C, Maurel P, Somsák L, Docsa T, Gergely P, Praly JP, Azay-Milhau J, Vidal S.
    Eur J Med Chem; 2016 Jan 27; 108():444-454. PubMed ID: 26708111
    [Abstract] [Full Text] [Related]

  • 7. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors.
    Gregus Z, Németi B.
    Toxicol Sci; 2007 Nov 27; 100(1):44-53. PubMed ID: 17693424
    [Abstract] [Full Text] [Related]

  • 8. Prolonged inhibition of glycogen phosphorylase in livers of Zucker Diabetic Fatty rats models human glycogen storage diseases.
    Floettmann E, Gregory L, Teague J, Myatt J, Hammond C, Poucher SM, Jones HB.
    Toxicol Pathol; 2010 Apr 27; 38(3):393-401. PubMed ID: 20215584
    [Abstract] [Full Text] [Related]

  • 9. Lack of hepatic "interregulation" during inhibition of glycogenolysis in a canine model.
    Fosgerau K, Mittelman SD, Sunehag A, Dea MK, Lundgren K, Bergman RN.
    Am J Physiol Endocrinol Metab; 2001 Aug 27; 281(2):E375-83. PubMed ID: 11440915
    [Abstract] [Full Text] [Related]

  • 10. Glycogen phosphorylase as a molecular target for type 2 diabetes therapy.
    Oikonomakos NG.
    Curr Protein Pept Sci; 2002 Dec 27; 3(6):561-86. PubMed ID: 12470212
    [Abstract] [Full Text] [Related]

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Dec 27; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 12. Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase.
    Hoover DJ, Lefkowitz-Snow S, Burgess-Henry JL, Martin WH, Armento SJ, Stock IA, McPherson RK, Genereux PE, Gibbs EM, Treadway JL.
    J Med Chem; 1998 Jul 30; 41(16):2934-8. PubMed ID: 9685232
    [No Abstract] [Full Text] [Related]

  • 13. New hepatic targets for glycaemic control in diabetes.
    Agius L.
    Best Pract Res Clin Endocrinol Metab; 2007 Dec 30; 21(4):587-605. PubMed ID: 18054737
    [Abstract] [Full Text] [Related]

  • 14. Kinetic and functional characterization of 1,4-dideoxy-1, 4-imino-d-arabinitol: a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice.
    Fosgerau K, Westergaard N, Quistorff B, Grunnet N, Kristiansen M, Lundgren K.
    Arch Biochem Biophys; 2000 Aug 15; 380(2):274-84. PubMed ID: 10933882
    [Abstract] [Full Text] [Related]

  • 15. Hormone-stimulated glucose production from glycogen in hepatocytes from streptozotocin diabetic rats.
    Lavoie L, van de Werve G.
    Metabolism; 1991 Oct 15; 40(10):1031-6. PubMed ID: 1658543
    [Abstract] [Full Text] [Related]

  • 16. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Oct 15; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of glycogenolysis enhances gluconeogenic precursor uptake by the liver of conscious dogs.
    Shiota M, Jackson PA, Bischoff H, McCaleb M, Scott M, Monohan M, Neal DW, Cherrington AD.
    Am J Physiol; 1997 Nov 15; 273(5):E868-79. PubMed ID: 9374671
    [Abstract] [Full Text] [Related]

  • 18. Glucose analog inhibitors of glycogen phosphorylases as potential antidiabetic agents: recent developments.
    Somsák L, Nagya V, Hadady Z, Docsa T, Gergely P.
    Curr Pharm Des; 2003 Nov 15; 9(15):1177-89. PubMed ID: 12769745
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogen synthesis in primary rat hepatocytes.
    Zibrova D, Grempler R, Streicher R, Kauschke SG.
    Biochem J; 2008 Jun 01; 412(2):359-66. PubMed ID: 18298402
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of glycogen phosphorylase in the context of type 2 diabetes, with focus on recent inhibitors bound at the active site.
    Praly JP, Vidal S.
    Mini Rev Med Chem; 2010 Oct 01; 10(12):1102-26. PubMed ID: 20716051
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.